Immunotherapy of colorectal cancer: New perspectives after a long path

Cirino Botta, Silvia Zappavigna, Cirino Botta, Domenico Ciliberto, Pierpaolo Pastina, Rossana Ingargiola, Pierpaolo Correale, Michele Caraglia, Pierfrancesco Tassone, Luigi Pirtoli, Pierosandro Tagliaferri

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


Although significant therapeutic improvement has been achieved in the last 10 years, the survival of metastatic colorectal cancer patients remains in a range of 28 to 30 months. Presently, systemic treatment includes combination chemotherapy with oxaliplatin and/or irinotecan together with a backbone of 5-fluorouracil/levofolinate, alone or in combination with monoclonal antibodies to VEGFA (bevacizumab) or EGF receptor (cetuximab and panitumumab). The recent rise of immune checkpoint inhibitors in the therapeutic scenario has renewed scientific interest in the investigation of immunotherapy in metastatic colorectal cancer patients. According to our experience and view, here, we review the immunological strategies investigated for the treatment of this disease, including the use of tumor target-specific cancer vaccines, chemo-immunotherapy and immune checkpoint inhibitors.
Original languageEnglish
Pages (from-to)1281-1292
Number of pages12
Publication statusPublished - 2016

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Immunotherapy of colorectal cancer: New perspectives after a long path'. Together they form a unique fingerprint.

Cite this